ES2721935T3 - Anticuerpos anti-BAG3 para uso terapéutico - Google Patents

Anticuerpos anti-BAG3 para uso terapéutico Download PDF

Info

Publication number
ES2721935T3
ES2721935T3 ES14716010T ES14716010T ES2721935T3 ES 2721935 T3 ES2721935 T3 ES 2721935T3 ES 14716010 T ES14716010 T ES 14716010T ES 14716010 T ES14716010 T ES 14716010T ES 2721935 T3 ES2721935 T3 ES 2721935T3
Authority
ES
Spain
Prior art keywords
therapeutic use
bag3 antibodies
bag3
antibodies
extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14716010T
Other languages
English (en)
Spanish (es)
Inventor
Maria Caterina Turco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biouniversa SRL
Original Assignee
Biouniversa SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa SRL filed Critical Biouniversa SRL
Application granted granted Critical
Publication of ES2721935T3 publication Critical patent/ES2721935T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Multiple-Way Valves (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14716010T 2013-03-18 2014-03-04 Anticuerpos anti-BAG3 para uso terapéutico Active ES2721935T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000403A ITMI20130403A1 (it) 2013-03-18 2013-03-18 Anticorpi anti-bag3 per uso terapeutico
PCT/IB2014/059416 WO2014147503A2 (en) 2013-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use

Publications (1)

Publication Number Publication Date
ES2721935T3 true ES2721935T3 (es) 2019-08-06

Family

ID=48227407

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14716010T Active ES2721935T3 (es) 2013-03-18 2014-03-04 Anticuerpos anti-BAG3 para uso terapéutico
ES14830409.0T Active ES2650942T3 (es) 2013-03-18 2014-11-19 Válvula, en particular válvula de descarga de agua para inodoros

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14830409.0T Active ES2650942T3 (es) 2013-03-18 2014-11-19 Válvula, en particular válvula de descarga de agua para inodoros

Country Status (9)

Country Link
US (2) US20150329622A1 (https=)
EP (1) EP2976104B1 (https=)
JP (1) JP6475225B2 (https=)
KR (1) KR20150129649A (https=)
CN (1) CN104902927A (https=)
CA (1) CA2895472C (https=)
ES (2) ES2721935T3 (https=)
IT (1) ITMI20130403A1 (https=)
WO (1) WO2014147503A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
ITUB20155097A1 (it) * 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
IT201600111877A1 (it) * 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
CN114533877B (zh) * 2022-03-09 2023-07-04 上海交通大学医学院附属第九人民医院 Bag3抑制剂在制备治疗瘢痕产品中的用途
WO2026074330A1 (en) 2024-10-01 2026-04-09 Fibrosys S.R.L. Antibodies and diagnostic methods for detecting bag3 protein in clinical samples

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774355B2 (en) * 1998-09-09 2004-06-24 Burnham Institute, The Novel bag proteins and nucleic acid molecules encoding them
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2009014759A2 (en) * 2007-07-25 2009-01-29 The Trustess Of Columbia University In The City Of New York Methods of inhibiting vzv replication and related compositions
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
EP2676966A1 (en) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 as biochemical serum and tissue marker

Also Published As

Publication number Publication date
WO2014147503A3 (en) 2014-12-04
US20150329622A1 (en) 2015-11-19
ITMI20130403A1 (it) 2014-09-19
CN104902927A (zh) 2015-09-09
JP2016516078A (ja) 2016-06-02
ES2650942T3 (es) 2018-01-23
WO2014147503A2 (en) 2014-09-25
JP6475225B2 (ja) 2019-02-27
US20190010221A1 (en) 2019-01-10
CA2895472A1 (en) 2014-09-25
KR20150129649A (ko) 2015-11-20
EP2976104A2 (en) 2016-01-27
EP2976104B1 (en) 2019-01-30
US11117957B2 (en) 2021-09-14
CA2895472C (en) 2022-07-05

Similar Documents

Publication Publication Date Title
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
UY35399A (es) Conjugados de fármacos con anticuerpos
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
MX375020B (es) Anticuerpos anti-alfa-sinucleina y métodos de uso.
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
PH12016500482A1 (en) Combination therapy with an anti-ang2 antibody and a cd40 agonist
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112015030356A2 (pt) métodos de tratamento de uma taupatia